Intellia Therapeutics Broadcasts Closing of $201 Million Public Providing of Widespread Inventory, Together with Full Train of Underwriters’ Choice to Buy Extra Shares

CAMBRIDGE, Mass., Dec. 04, 2020 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a number one genome enhancing firm centered on creating healing therapeutics utilizing CRISPR/Cas9 expertise each in vivo and ex vivo, introduced right this moment the closing of an underwritten public providing of 5,513,699 shares of its widespread inventory, together with the train in full by the underwriters of their choice to buy an extra 719,178 shares, on the public providing value of $36.50 per share. The gross proceeds raised within the providing, earlier than underwriting reductions and commissions and bills of the providing, have been roughly $201 million.

Goldman Sachs & Co. LLC, Jefferies LLC and SVB Leerink LLC acted as joint book-running managers for the providing.

The shares of widespread inventory have been provided by Intellia pursuant to a shelf registration assertion that was beforehand filed with the U.S. Securities and Alternate Fee (SEC) and mechanically grew to become efficient upon submitting. A ultimate prospectus complement and accompanying prospectus referring to and describing the phrases of the providing was filed with the SEC on December 2, 2020. The ultimate prospectus complement and accompanying prospectus referring to the providing could also be obtained from: Goldman Sachs & Co. LLC, by mail at 200 West Road, New York, NY 10282, Consideration: Prospectus Division, by phone at (866) 471-2526, or by e mail at prospectus-ny@ny.e mail.gs.com; or Jefferies LLC, by mail at 520 Madison Avenue, 2nd Flooring, New York, NY 10022, Consideration: Fairness Syndicate Prospectus Division, by phone at (877) 547-6340, or by e mail at Prospectus_Department@Jefferies.com; or SVB Leerink LLC, by mail at One Federal Road, thirty seventh Flooring, Boston, MA 02110, Consideration: Syndicate Division, by phone at (800) 808-7525, ext. 6132, or by e mail at syndicate@svbleerink.com; or by accessing the SEC’s web site at www.sec.gov.

This press launch shall not represent a suggestion to promote or the solicitation of a suggestion to purchase these securities, nor shall there be any sale of those securities in any state or jurisdiction during which such supply, solicitation or sale can be illegal previous to registration or qualification below the securities legal guidelines of any such state or jurisdiction.

About Intellia Therapeutics

Intellia Therapeutics is a number one genome enhancing firm centered on creating proprietary, healing therapeutics utilizing the CRISPR/Cas9 system.

Ahead-Trying Statements

This press launch comprises forward-looking statements throughout the which means of the Personal Securities Litigation Reform Act of 1995, as amended, together with, with out limitation, statements concerning Intellia’s anticipated public providing. The phrases “might,” “will,” “might,” “would,” “ought to,” “anticipate,” “plan,” “anticipate,” “intend,” “imagine,” “estimate,” “predict,” “mission,” “potential,” “proceed,” “goal” and comparable expressions are supposed to establish forward-looking statements, though not all forward-looking statements include these figuring out phrases. Any forward-looking statements on this press launch are primarily based on administration’s present expectations and beliefs and are topic to a lot of dangers, uncertainties and necessary components which will trigger precise occasions or outcomes to vary materially from these expressed or implied by any forward-looking statements contained on this press launch, together with, with out limitation, uncertainties associated to market situations. These and different dangers and uncertainties are described in larger element within the part entitled “Threat Components” in Intellia’s most up-to-date annual report on Type 10-Okay and quarterly report on Type 10-Q filed with the SEC, in addition to discussions of potential dangers, uncertainties, and different necessary components in Intellia’s different filings with the SEC, together with these contained or included by reference within the ultimate prospectus complement and accompanying prospectus associated to the general public providing filed with the SEC. Any forward-looking statements contained on this press launch signify Intellia’s views solely as of the date hereof and shouldn’t be relied upon as representing its views as of any subsequent date. Intellia explicitly disclaims any obligation to replace any forward-looking statements, besides as required by regulation.

Intellia Contacts: 

Traders:
Lina Li
Affiliate Director
Investor Relations
+1 857-706-1612
lina.li@intelliatx.com

Media:
Jennifer Mound Smoter
Senior Vice President
Exterior Affairs & Communications
+1 857-706-1071
jenn.smoter@intelliatx.com

Sarepta Therapeutics to Share Scientific Replace for SRP-5051, its Investigational PPMO for the Therapy of Duchenne Muscular Dystrophy

CAMBRIDGE, Mass., Dec. 04, 2020 (GLOBE NEWSWIRE) — Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the chief in precision genetic medication for uncommon ailments, right this moment introduced that on Monday, Dec. 7, 2020 at 8:30 am Jap Time (ET), it can host a webcast and convention name to current interim knowledge from the MOMENTUM examine, a multiple-ascending dose scientific trial of SRP-5051 for the therapy of Duchenne muscular dystrophy. SRP-5051 is the primary investigational therapy utilizing Sarepta’s next-generation PPMO platform, which is designed round a proprietary cell-penetrating peptide conjugated to Sarepta’s phosphorodiamidate morpholino oligomer (PMO) spine with the aim of accelerating drug focus in muscle tissue.

The presentation will probably be webcast dwell below the investor relations part of Sarepta’s web site at https://investorrelations.sarepta.com/events-presentations and slides will probably be archived there following the decision for one 12 months. Please connect with Sarepta’s web site a number of minutes previous to the beginning of the printed to make sure satisfactory time for any software program obtain which may be obligatory. The convention name could also be accessed by dialing (844) 534-7313 for home callers and (574) 990-1451 for worldwide callers. The passcode for the decision is 6382259. Please specify to the operator that you simply wish to be part of the “Sarepta-hosted Scientific Replace for MOMENTUM name.”

About Sarepta Therapeutics
At Sarepta, we’re main a revolution in precision genetic medication and each day is a chance to alter the lives of individuals residing with uncommon illness. The Firm has constructed a formidable place in Duchenne muscular dystrophy (DMD) and in gene therapies for limb-girdle muscular dystrophies (LGMDs), mucopolysaccharidosis sort IIIA, Charcot-Marie-Tooth (CMT), and different CNS-related issues, with greater than 40 applications in numerous phases of improvement. The Firm’s applications and analysis focus span a number of therapeutic modalities, together with RNA, gene remedy and gene enhancing. For extra data, please go to www.sarepta.com or comply with us on Twitter, LinkedIn, Instagram and Facebook.

Web Posting of Info

We routinely put up data which may be necessary to buyers within the ‘Traders’ part of our web site at www.sarepta.com. We encourage buyers and potential buyers to seek the advice of our web site usually for necessary details about us.

Supply: Sarepta Therapeutics, Inc.

Sarepta Therapeutics, Inc.
Traders:
Ian Estepan, 617-274-4052, iestepan@sarepta.com

Media:
Tracy Sorrentino, 617-301-8566, tsorrentino@sarepta.com

Reata Prescription drugs, Inc. Declares Closing of Class A Widespread Inventory Providing

PLANO, Texas, Dec. 04, 2020 (GLOBE NEWSWIRE) — Reata Prescription drugs, Inc. (Nasdaq: RETA) (“Reata” or the “Firm”), a clinical-stage biopharmaceutical firm, at this time introduced the closing of its beforehand introduced underwritten public providing of two,000,000 shares by the Firm of its Class A typical inventory, at a value to the general public of $140.85 per share, for gross proceeds of $281.7 million. Reata has granted the underwriters a 30-day choice to buy 300,000 further shares of its Class A typical inventory, on the identical phrases and situations because the shares provided within the public providing.

Barclays Capital Inc. and Goldman Sachs & Co. LLC acted because the joint book-running managers for the providing.

The securities described above have been provided pursuant to an mechanically efficient shelf registration assertion on Kind S-3. The providing was performed solely via a written prospectus and prospectus complement that kind part of the registration assertion. A closing prospectus complement and accompanying prospectus regarding the providing have been filed with the Securities and Change Fee (the “SEC”) and can be found on the SEC’s web site at www.sec.gov. Copies of the ultimate prospectus complement and the accompanying prospectus can also be obtained by request at Barclays Capital Inc., Consideration: Broadridge Monetary Options, 1155 Lengthy Island Avenue, Edgewood, New York 11717, phone: 1-888-603-5847, or by emailing Barclaysprospectus@broadridge.com; or Goldman Sachs & Co. LLC, Prospectus Division, 200 West Avenue, New York, NY 10282, phone: 1-866-471-2526, facsimile: 212-902-9316 or by emailing Prospectus-ny@ny.e-mail.gs.com.

This information launch is for informational functions solely and shall not represent a suggestion to promote or the solicitation of a suggestion to purchase, nor shall there be any sale of those securities, in any state or jurisdiction through which such supply, solicitation or sale of those securities can be illegal previous to registration or qualification below the securities legal guidelines of any such state or jurisdiction.

About Reata Prescription drugs, Inc.

Reata is a clinical-stage biopharmaceutical firm that develops novel therapeutics for sufferers with severe or life-threatening ailments by concentrating on molecular pathways concerned within the regulation of mobile metabolism and irritation. Reata’s two most superior medical candidates, bardoxolone methyl (“bardoxolone”) and omaveloxolone, goal the vital transcription issue Nrf2 that promotes restoration of mitochondrial operate, discount of oxidative stress, and inhibition of pro-inflammatory signaling. Bardoxolone and omaveloxolone are investigational medication, and their security and efficacy haven’t been established by any company.

Ahead-Trying Statements

This press release contains sure disclosures that include “forward-looking statements,” together with, with out limitation, statements relating to the public providing and the anticipated use of web proceeds of the providing, the success, value and timing of our product improvement actions and medical trials, our plans to analysis, develop and commercialize our product candidates, our plans to submit regulatory filings, and our skill to acquire and retain regulatory approval of our product candidates. You’ll be able to determine forward-looking statements as a result of they include phrases resembling “believes,” “will,” “could,” “goals,” “plans,” “mannequin,” and “expects.” Ahead-looking statements are primarily based on Reata’s present expectations and assumptions. As a result of forward-looking statements relate to the long run, they’re topic to inherent uncertainties, dangers, and adjustments in circumstances which will differ materially from these contemplated by the forward-looking statements, that are neither statements of historic reality nor ensures or assurances of future efficiency. Necessary components that would trigger precise outcomes to vary materially from these within the forward-looking statements embody, however usually are not restricted to, (i) the uncertainties associated to market situations and the completion of the general public providing on the anticipated phrases or in any respect; (ii) the timing, prices, conduct, and consequence of our clinical trials and future preclinical research and medical trials, together with the timing of the initiation and availability of knowledge from such trials; (iii) the timing and probability of regulatory filings and approvals for our product candidates; (iv) whether or not regulatory authorities decide that further trials or information are needed as a way to receive approval; (v) the potential market measurement and the dimensions of the affected person populations for our product candidates, if authorized for business use, and the market alternatives for our product candidates; and (vi) different components set forth in Reata’s filings with the U.S. Securities and Change Fee, together with its Annual Report on Kind 10-Okay for the 12 months ended December 31, 2019 and Quarterly Report on Kind 10–Q for the quarter ended March 31, 2020, below the caption “Threat Components.” The forward-looking statements converse solely as of the date made and, aside from as required by regulation, we undertake no obligation to publicly replace or revise any forward-looking statements, whether or not on account of new info, future occasions, or in any other case.

Contact:
Reata Prescription drugs, Inc.
(972) 865-2219

Investor Relations:
Vinny Jindal
(469) 374-8721
ir@reatapharma.com

ot for distribution to United States newswire companies or for launch publication, distribution or dissemination instantly, or not directly, in complete or partially, in or into the US.

TORONTO, Dec. 04, 2020 (GLOBE NEWSWIRE) — PsyBio Therapeutics, Inc. (“PsyBio”) and Leo Acquisitions Corp. (NEX: LEQ.H) (“Leo” or the “Firm”) are happy to announce the closing of the beforehand introduced brokered personal placement (the “Financing”) of subscription receipts (the “Subscription Receipts”) of PsyBio Therapeutics Financing Inc. (“Finco”), a particular goal British Columbia firm integrated solely for the aim of the Financing and wholly-owned by the Chief Govt Officer of PsyBio, at a worth of CAD$0.35 per Subscription Receipt for mixture gross proceeds of CAD$14,493,394, roughly thrice the unique CAD$5.0 million goal, with vital US and Canadian institutional investor assist.

Eight Capital acted as lead agent in reference to the Financing (the “Lead Agent”) along with Canaccord Genuity Corp. (along with the Lead Agent, the “Brokers”) to supply the Subscription Receipts on the market on a “finest efforts” company foundation.

“We’re terribly happy to have skilled such a profitable financing working with Eight Capital and Canaccord Genuity Corp.” stated Evan Levine, Chairman and Chief Govt Officer of PsyBio Therapeutics. “PsyBio is within the enterprise of discovering and creating a portfolio of psychoactive drugs and this providing, together with the participation by distinguished well being care institutional traders, validates our imaginative and prescient {that a} paradigm shift for the remedy of psychological well being points is lengthy overdue.”

Evan continued “Our proprietary biosynthesis drug discovery platform is predicted to allow the speedy technology of extremely secure compounds far cheaper, quicker and greener than some other revealed methodology. The capital acquired from this providing will allow PsyBio to proceed to work in the direction of the invention of recent precious goal molecules, and additional the motion of our merchandise in the direction of Investigational New Drug Functions.”

The Firm has filed patent purposes regarding psilocybin and its intermediates and expects to file new patent purposes over the approaching 12 months based mostly on different hallucinogenic crops, fungi and non-natural compounds with psychoactive properties.

Abstract of the Financing

The Financing was accomplished in reference to a collection of transactions that may outcome within the reverse takeover of Leo by the shareholders of PsyBio (the “Transaction”). The Transaction will represent Leo’s “Qualifying Transaction” as such time period is outlined in Coverage 2.4 of the Company Finance Handbook of the TSX Enterprise Alternate (the “TSXV”). Additional particulars of the Transaction have been beforehand introduced by Leo on October 6, 2020, October 26, 2020 and December 2, 2020. References herein to the “Ensuing Issuer” consult with Leo following the completion of the Transaction.

An mixture of 41,409,698 Subscription Receipts have been issued in reference to the Financing. Every Subscription Receipt entitles the holder thereof to obtain, upon the satisfaction or waiver (to the extent such waiver is permitted) of sure escrow launch circumstances (the “Escrow Launch Situations”) previous to the Escrow Launch Deadline (as outlined beneath), together with all circumstances precedent to the Transaction being glad, and with out cost of extra consideration therefor, one frequent share within the capital of Finco (every, a “Finco Share”). On completion of the Transaction, every Finco Share underlying the Subscription Receipts can be exchanged for one subordinate voting share of the Ensuing Issuer (every, a “Subordinate Voting Share”), all in accordance with the phrases of the enterprise mixture settlement among the many Firm, PsyBio and Finco, 1276949 B.C. Ltd. and Eluss, Inc., dated December 2, 2020 (the “Definitive Settlement”) governing the phrases of the Transaction.

In reference to the Financing, the Brokers are entitled to obtain a money fee of CAD$527,229 (the “Brokers’ Fee”)and 1,506,368 compensation warrants (the “Compensation Warrants”),. Every Compensation Warrant is exercisable to amass one Finco Share on the Challenge Value for a interval of 24 months from the satisfaction of the Escrow Launch Situations (the “Train Interval”). Upon completion of the Transaction, every holder of Compensation Warrants will obtain Subordinate Voting Shares in lieu of Finco Shares upon train of the Compensation Warrants, together with the cost therefor. The Brokers are additionally entitled to obtain, in reference to sure advisory companies supplied by the Brokers pursuant to the phrases of an advisory settlement among the many Brokers and Finco, money advisory charges of CAD$374,000 (the “Finance Payment”) and 1,069,000 advisor warrants (every, an “Advisor Warrant”), with every Advisor Warrant having the identical traits because the Compensation Warrants. On closing of the Financing, the Brokers acquired cost of fifty% of the Brokers’ Fee, 50% of the Finance Payment and have been issued all the Compensation Warrants and Advisor Warrants. The remaining 50% of the Brokers’ Fee and 50% of the Finance Payment can be paid to the Brokers upon escrow launch.

The gross proceeds of the Financing (much less an quantity equal to 50% of the Brokers’ Fee, 50% of the Finance Payment, and all the cheap prices and bills of the Brokers in reference to the Financing) (the “Escrowed Funds”) have been deposited in escrow with the subscription receipt agent till the satisfaction of the Escrow Launch Situations, together with that each one circumstances precedent to the Transaction have been glad or waived.

Within the occasion that the Escrow Launch Situations haven’t been glad by February 28, 2021, or such different date as Finco and the Lead Agent might decide (the “Escrow Launch Deadline”), or Finco advises the Lead Agent or declares to the general public that it doesn’t intend to fulfill the Escrow Launch Situations, or that the Transaction has been terminated in accordance with the phrases of the Definitive Settlement, the mixture difficulty worth of the Subscription Receipts along with any earned curiosity shall be returned to the relevant holders of the Subscription Receipts (internet of any relevant withholding taxes), and such Subscription Receipts shall be routinely cancelled and be of no additional power and impact.

All Subscription Receipts issued in reference to the Financing are topic to a statutory maintain interval in accordance with Canadian securities legal guidelines. Following completion of the Transaction, the Subordinate Voting Shares acquired upon the alternate of Finco Shares underlying the Subscription Receipts won’t be topic to a statutory maintain interval in Canada.

Upon completion of the Transaction, the proceeds of the Financing are anticipated for use principally to fund the Transaction, and for analysis and growth, manufacturing, company and normal working capital functions.

About PsyBio Therapeutics

PsyBio is a US-based biotechnology firm creating a brand new class of medication supposed for the remedy of psychological well being challenges and different problems. In collaboration with Miami College based mostly in Oxford, Ohio, PsyBio has retained the worldwide unique rights to a proprietary platform know-how that biologically synthesizes psilocybin and different focused subsequent technology psychoactive compounds which are produced naturally in fungi and crops. Administration of PsyBio expects that the know-how will allow the speedy technology of those extremely secure psychoactive compounds cheaper, quicker and greener than different revealed strategies. PsyBio was integrated beneath the legal guidelines of the State of Delaware on January 21, 2020 and isn’t a “reporting issuer” beneath relevant securities laws in any jurisdiction and its securities aren’t listed for buying and selling on any inventory alternate.

About Leo Acquisitions

Leo was integrated beneath the Enterprise Companies Act (Ontario) on October 28, 2009 and is a Capital Pool Firm (as outlined in TSXV Coverage 2.4 – Capital Pool Firms of the Company Finance Handbook). Leo is listed on the NEX board of the TSXV. Leo has no industrial operations and no property apart from money.

Cautionary Notice Concerning Ahead-Wanting Statements

This press launch comprises statements that represent “forward-looking data” (“forward-looking data”) inside the which means of the relevant Canadian securities laws. All statements, apart from statements of historic truth, are forward-looking data and are based mostly on expectations, estimates and projections as on the date of this information launch. Any assertion that discusses predictions, expectations, beliefs, plans, projections, goals, assumptions, future occasions or efficiency (usually however not at all times utilizing phrases akin to “expects”, or “doesn’t anticipate”, “is predicted”, “anticipates” or “doesn’t anticipate”, “plans”, “finances”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such phrases and phrases or stating that sure actions, occasions or outcomes “might” or “may”, “would”, “may” or “will” be taken to happen or be achieved) aren’t statements of historic truth and could also be forward-looking data. In disclosing the forward-looking data contained on this press launch, the Firm has made sure assumptions, together with that: all relevant shareholder and regulatory approvals for the Transaction can be acquired; the Transaction can be accomplished on the phrases set forth on this press launch, on acceptable phrases or in any respect; PsyBio can be profitable in defending its mental property inside the subsequent 12 months and submitting new patent purposes inside that timeframe; the Firm’s success in discovering new precious goal molecules; the flexibility of PsyBio to acquire Investigation New Drug Functions; the satisfaction of the Escrow Launch Situations can be met; the usage of the gross proceeds of the Financing can be as set forth on this press launch; and the protection and efficacy of PsyBio’s know-how and that such know-how can be cheaper, quicker and greener than different revealed strategies. Though the Firm believes that the expectations mirrored in such forward-looking data are cheap, it may give no assurance that the expectations of any forward-looking data will show to be appropriate. Recognized and unknown dangers, uncertainties, and different elements which can trigger the precise outcomes and future occasions to vary materially from these expressed or implied by such forward-looking data. Such elements embrace, however aren’t restricted to: availability of financing; delay or failure to obtain board, shareholder or regulatory approvals; compliance with in depth authorities rules; home and overseas legal guidelines and rules adversely affecting PsyBio’s enterprise and outcomes of operations; decreases within the prevailing course of for psilocybin and nutraceutical merchandise within the markets through which PsyBio and the Ensuing Issuer will function; the affect of COVID-19; and normal enterprise, financial, aggressive, political and social uncertainties. Accordingly, readers mustn’t place undue reliance on the forward-looking data contained on this press launch. Besides as required by regulation, the Firm disclaims any intention and assumes no obligation to replace or revise any forward-looking data to mirror precise outcomes, whether or not because of new data, future occasions, adjustments in assumptions, adjustments in elements affecting such forward-looking data or in any other case.

PsyBio makes no medical, remedy or well being profit claims about PsyBio’s proposed merchandise. The U.S. Meals and Drug Administration (the “FDA”) or different comparable regulatory authorities haven’t evaluated claims relating to psilocybin and different subsequent technology psychoactive compounds. The efficacy of such merchandise haven’t been confirmed by FDA-approved analysis. There isn’t any assurance that the usage of psilocybin and different psychoactive compounds can diagnose, deal with, treatment or forestall any illness or situation. Vigorous scientific analysis and medical trials are wanted. PsyBio has not carried out medical trials for the usage of its proposed PsyBio IP. Any references to high quality, consistency, efficacy and security of potential merchandise don’t indicate that PsyBio verified such in medical trials or that PsyBio will full such trials. If PsyBio can not get hold of the approvals or analysis essential to commercialize its enterprise, it might have a cloth hostile impact on the PsyBio’s efficiency and operations.

For additional data contact: 

Evan Levine
CEO, PsyBio Therapeutics, Inc.
p: 513-449-9585
e: evan@psybiolife.com

Gerry Goldberg
CEO, Leo Acquisitions Corp.
e: gerrygoldbergcpa@gmail.com

This information launch doesn’t represent a proposal to promote or a solicitation of a proposal to purchase any of the securities in the US. The securities haven’t been and won’t be registered beneath the US Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities legal guidelines and is probably not supplied or offered inside the US or to U.S. Individuals except registered beneath the U.S. Securities Act and relevant state securities legal guidelines or an exemption from such registration is offered. 

All data contained on this information launch with respect to the Firm and PsyBio was provided by the events respectively, for inclusion herein, with out unbiased assessment by the opposite celebration, and every celebration and its administrators and officers have relied on the opposite celebration for any data in regards to the different celebration.

Completion of the Transaction is topic to quite a lot of circumstances, together with however not restricted to, TSXV acceptance and, if relevant pursuant to TSXV necessities, majority of the minority shareholder approval. The place relevant, the Transaction can not shut till the required shareholder approval is obtained. There may be no assurance that the Transaction can be accomplished as proposed or in any respect. 

Traders are cautioned that, besides as disclosed within the administration data round or submitting assertion to be ready in reference to the Transaction, any data launched or acquired with respect to the Transaction is probably not correct or full and shouldn’t be relied upon. Buying and selling within the securities of a capital pool firm must be thought of extremely speculative. 

The TSXV has by no means handed upon the deserves of the proposed Transaction and has neither accredited nor disapproved the contents of this press launch. Neither the TSXV nor its Regulation Providers Supplier (as that time period is outlined within the insurance policies of the TSXV) accepts duty for the adequacy or accuracy of this launch.